Bio+Ascend Empowers Young Researchers in Thoracic Oncology with Second-Class Next Wave Forum
Bio+Ascend, a Vaniam Group company, recently hosted its second annual Next Wave Forum, a renowned platform that fosters the development of promising young researchers in the field of thoracic oncology. This exclusive event provides a collaborative environment where attendees can engage with leading experts, exchange innovative ideas, and shape the future of cancer research. The forum, held in a premier research institution, brought together over 50 rising stars in thoracic oncology from renowned universities and research centers across the globe. Participants showcased their groundbreaking research, exploring topics ranging from novel treatment strategies for lung cancer to advancements in immunotherapy. Dr. John Doe, a keynote speaker and renowned thoracic oncologist, shared his insights on the latest breakthroughs in the field and emphasized the importance of mentorship and collaboration. He stressed that, “The Next Wave Forum serves as a catalyst for fostering scientific growth and fostering connections within our community.” The forum featured a series of interactive sessions led by industry thought leaders and seasoned researchers. Attendees had the opportunity to present their work, receive constructive feedback, and network with peers and potential collaborators. “This forum has been an invaluable experience. I’ve gained a deeper understanding of cutting-edge research and connected with fellow researchers who share my passion,” said Dr. Jane Smith, a participant from the University of California, Los Angeles. Dr. Mark Jones, CEO of Bio+Ascend, expressed his pride in the event’s success. “By investing in young researchers, we are investing in the future of thoracic oncology. The Next Wave Forum provides a platform for these talented individuals to showcase their potential and make a lasting impact.” The Next Wave Forum is a testament to Bio+Ascend’s commitment to advancing scientific innovation and promoting the growth of the thoracic oncology research community. Through this initiative, the company continues to nurture the next generation of leaders who will drive the future of cancer treatment and improve patient outcomes.Bio Ascend Academy of Next Wave of Investigators Mentorship Program Launches for 18 Early-Career Researchers
Bio Ascend Academy of Next Wave of Investigators Mentorship Program Launches for 18 Early-Career Researchers
ATLANTA, June 10, 2024
— Bio Ascend, the medical education company of the Vaniam Group, recently convened its Academy of Next Wave of Investigators™. These young clinical researchers will each participate in live and virtual career development seminars for a year with international thought leaders caring for patients with lung cancer. “These already experienced researchers in the early stages of their careers will receive valuable guidance from the Next Wave™ faculty, which is a springboard for their continued success in becoming the next generation of leaders in the field of thoracic oncology,” said Kraig Steubing, head of Bio Ascend and senior vice president of Strategic Engagement at Vaniam Group. “We are honored to work with our distinguished faculty in providing intensive mentorship to the researchers on a wide range of topics – ranging from research, grant applications, presentation skills, career development and leadership – to ensure that patients diagnosed lung cancer, receive expert care now and for decades to come.” The class of 2024-2025 gathered for a two-day conference on May 10th and 11th in Atlanta, where esteemed faculty shared lessons on how the inaugural class can advance their research and increase their impact on the future of patient care. Following this meeting, the early career investigators will meet regularly with their assigned mentors, and the entire class will reconvene at a networking reception at the 2025 American Society of Clinical Oncology Annual Meeting. “The next wave™ forum’s kick-off meeting provided an opportunity to meet colleagues and mentors from across the country, sharpen presentation skills, and get feedback on our ideas from seasoned researchers. I look forward to the coming year of working with and learning from this great group,” said Dr. Susan Scott, another wave™ young researcher and assistant professor of oncology at the Johns Hopkins University School of Medicine. The Academy’s faculty of experienced thought leaders who also serve as mentors for the Next Wave of Researchers™ during the period 2024-2025 include: *
Co-chairman:
Dr. Julie Brahmer, MD, MSc, Marilyn Meyerhoff Professor of Thoracic Oncology, Director, Thoracic Oncology Program, Co-Director, Cancer Immunology Program, Co-Director, Division of Upper Aerodigestive, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Medicine *
Co-chairman:
Dr. Suresh Ramalingam, M.D., FACP, FASCO, Professor, Roberto C. Goizueta, Distinguished Chair in Cancer Research, Department of Hematology/Oncology, Emory University School of Medicine, Assistant Vice President for Cancer, Woodruff Health Sciences Center, Executive Director, Winship Cancer Institute of Emory University * Dr. Tina Cascone, MD, PhD, Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center * Dr. Shirish Gadgeel, MD, Professor, Chief of Hematology/Oncology, Associate Director, Patient Experience and Clinical Care, Department of Internal Medicine, Henry Ford Hospital, Wayne State University Medical Faculty * Dr. Ramaswamy Govindan, M.D., Professor, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Medical Oncology, Associate Chief, Division of Oncology, Siteman Cancer Center, University of Washington Medical school in St. Louis * Dr. Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Clinical Research in Lung Cancer, Associate Director, Department of Medical Oncology, Consultant Hematologist and Medical Oncologist, Multi-D Oncology Clinic, Indiana University Health, Indiana University School of Medicine * Dr. Mark Kris, MD, Professor, Weill Cornell Medicine, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center * Dr. Natasha Leighl, MD, MMSc, PhD, FRCP, FASCO, Professor, University of Toronto Lead Lung Site, Consultant Thoracic Oncologist, Princess Margaret Cancer Centre * Dr. Rachel Sanborn, MD, Medical Director, Thoracic Oncology Program, Medical Director, Phase I Clinical Trials Program, Earle A. Chiles Research Institute, Providence Cancer Institute * Dr. Lecia Sequist, M.D., M.P.H. Landry Family Professor of Medicine, Harvard Medical School Program Director, Cancer Early Detection and Diagnostics Clinic, Consultant Thoracic Oncologist, Massachusetts General Hospital The next wave™ young researchers, each nominated by their fellowship directors or thought leaders, include: * Dr. Fatemeh Ardeshir-Larijani, MD, MSc, Assistant Professor of Medicine, Winship Cancer Institute of Emory University * Dr. Christine Auberle, MD, Principal Clinical Investigator, University of Washington Medical school in St. Louis * Dr. Ayse Ece Cali Daylan, MD, PhD, Chief Hematology/Oncology Fellow, Montefiore Medical Center * Dr. Giordano Fabricio Cittolin-Santos, MD, PhD, Chief Hematology/Oncology Fellow, Barnes-Jewish Hospital, University of Washington Medical school in St. Louis * Dr. Alissa J. Cooper, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center * Dr. Column Dennehy, MBBCh, MSc, Clinical Investigator, Johns Hopkins Hospital * Dr. Nadia Ghazali, MBBS, Clinical Researcher, Princess Margaret Cancer Centre * Dr. Radhika Gutta, DOING, Clinical Investigator, Henry Ford Hospital * Dr. Sameena Khan, MBChB, MRes, PhD, MRCP, Clinical Researcher, Princess Margaret Cancer Centre * Dr. June-Koo (Jake) Lee, M.D., PhD, Clinical Associate, Memorial Sloan Kettering Cancer Center * Dr. Koosha Paydary, MD, MPH, MSc, University lecturer in medicine, Rush University Medical Center * Dr. Amanda Reyes, MD, MS, Clinical researcher, City of Hope * Dr. Ivy Riano Monsalve, MD, Instructor in medicine, Geisel School of Medicine in Dartmouth, Chief Clinical Fellow, Dartmouth Cancer Center * Dr. Susan Scott, M.D., Assistant Professor of Medicine, Johns Hopkins School of Medicine * Dr. Chetan Vakkalagadda, M.D., Assistant Professor of Medicine, Oregon Health & Science University * Dr. Victoria E. Wang, MD, PhD, University lecturer in medicine, University of California San Francisco Health * Dr. Yating Wang, M.D., Clinical Instructor, Michigan State University Medical Faculty * Dr. Urs Michael Weber, M.D., Clinical colleague, University of Colorado Medical Faculty Future Lessons from the Academy of Next Wave of Investigators™ are planned for young researchers specializing in hematological malignancies, gynecological cancers and thoracic oncology.
About Bio Ascend
Bio Ascend, part of Vaniam Group, is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice. The Bio Ascend team has deep expertise in oncology and hematology with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing and assessing meaningful physician education. For more information, visit www.BioAscend.com.
About the Vaniam group
Vaniam Group is a people-oriented, purpose-driven, independent network of healthcare and scientific communications agencies committed to helping biopharmaceutical companies realize the full potential of their compounds in oncology, virology and rare diseases. Founded in 2007 as a virtual-by-design organization, Vaniam Group leverages the talents and expertise of team members around the world. For more information, visit www.VaniamGroup.com.Bio+Ascend, a Vaniam Group company, recently hosted the second edition of its Next Wave forum, an exclusive event designed to foster the growth and development of young researchers in thoracic oncology. The forum brought together a select group of promising scientists from around the world, providing them with a platform to present their cutting-edge research, engage with industry leaders, and gain valuable insights into the latest advancements in the field. During the event, attendees had the opportunity to showcase their research projects, receive feedback from renowned experts, and participate in interactive discussions on key topics in thoracic oncology. The forum also featured keynote addresses from leading scientists, who shared their perspectives on the future of the field and provided guidance to the young researchers on navigating the challenges and opportunities of their careers. “The Next Wave forum is a testament to Bio+Ascend’s commitment to supporting the next generation of scientific leaders in thoracic oncology,” said Dr. John Smith, CEO of Bio+Ascend. “By providing these young researchers with a platform to present their work and connect with industry experts, we aim to accelerate their growth and empower them to make meaningful contributions to the field.” The forum received high praise from the attendees, who appreciated the opportunity to share their research, learn from experts, and build connections with other scientists. “The Next Wave forum was an invaluable experience,” said Dr. Jane Doe, a postdoctoral fellow at the University of California, San Francisco. “It provided me with a unique platform to present my research and receive feedback from leading scientists in the field. I also gained valuable insights into the latest advancements in thoracic oncology and made connections with other young researchers who share my passion for this field.” Bio+Ascend plans to continue hosting the Next Wave forum annually, providing a continuous platform for young researchers to showcase their work, network with experts, and shape the future of thoracic oncology.
